Advertisement

Breast Cancer Research and Treatment

, Volume 169, Issue 3, pp 447–455 | Cite as

Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy

  • Yuri Tolkach
  • Heidrun Gevensleben
  • Ralph Bundschuh
  • Aydan Koyun
  • Daniela Huber
  • Christina Kehrer
  • Thomas Hecking
  • Mignon-Denise Keyver-Paik
  • Christina Kaiser
  • Hojjat Ahmadzadehfar
  • Markus Essler
  • Walther Kuhn
  • Glen KristiansenEmail author
Preclinical study

Abstract

Purpose

Prostate-specific membrane antigen (PSMA), a protein product of the folate hydrolase 1 (FOLH1) gene, is gaining increasing acceptance as a target for positron emission tomography/computer tomography (PET/CT) imaging in patients with several cancer types, including breast cancer. So far, PSMA expression in breast cancer endothelia has not been sufficiently characterized.

Methods

This study comprised 315 cases of invasive carcinoma of no special type (NST) and lobular breast cancer (median follow-up time 9.0 years). PSMA expression on tumor endothelia was detected by immunohistochemistry. Further, vascular mRNA expression of the FOLH1 gene (PSMA) was investigated in a cohort of patients with invasive breast cancer provided by The Cancer Genome Atlas (TCGA).

Results

Sixty percent of breast cancer cases exhibited PSMA-positive endothelia with higher expression rates in tumors of higher grade, NST subtype with Her2-positivity, and lack of hormone receptors. These findings were confirmed on mRNA expression levels. The highest PSMA rates were observed in triple-negative carcinomas (4.5 × higher than in other tumors). Further, a case of a patient with metastatic breast cancer showing PSMA expression in PET/CT imaging and undergoing PSMA radionuclide therapy is discussed in detail.

Conclusions

This study provides a rationale for the further development of PSMA-targeted imaging in breast cancer, especially in triple-negative tumors.

Keywords

FOLH1 PSMA Breast cancer PET/CT Expression Endothelium Marker 

Notes

Acknowledgements

No funding was received for this study.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Spatz S, Tolkach Y, Jung K et al (2017) Comprehensive evaluation of prostate specific membrane antigen expression in the vasculature of renal tumors: implications for imaging studies and prognostic role. J Urol.  https://doi.org/10.1016/j.juro.2017.08.079 PubMedCrossRefGoogle Scholar
  2. 2.
    Lütje S, Gomez B, Cohnen J et al (2017) Imaging of prostate-specific membrane antigen expression in metastatic differentiated thyroid cancer using 68 Ga-HBED-CC-PSMA PET/CT. Clin Nucl Med 42:20–25.  https://doi.org/10.1097/RLU.0000000000001454 CrossRefPubMedGoogle Scholar
  3. 3.
    Hangaard L, Jochumsen MR, Vendelbo MH, Bouchelouche K (2017) Metastases from colorectal cancer avid on 68 Ga-PSMA PET/CT. Clin Nucl Med 42:532–533.  https://doi.org/10.1097/RLU.0000000000001700 CrossRefPubMedGoogle Scholar
  4. 4.
    Haffner MC, Laimer J, Chaux A et al (2012) High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity. Mod Pathol 25:1079–1085.  https://doi.org/10.1038/modpathol.2012.66 CrossRefPubMedGoogle Scholar
  5. 5.
    Haffner MC, Kronberger IE, Ross JS et al (2009) Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum Pathol 40:1754–1761.  https://doi.org/10.1016/j.humpath.2009.06.003 CrossRefPubMedGoogle Scholar
  6. 6.
    Wernicke AG, Varma S, Greenwood EA et al (2014) Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers. APMIS 122:482–489.  https://doi.org/10.1111/apm.12195 CrossRefPubMedGoogle Scholar
  7. 7.
    Nomura N, Pastorino S, Jiang P et al (2014) Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases. Cancer Cell Int 14:26.  https://doi.org/10.1186/1475-2867-14-26 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Chang SS, Reuter VE, Heston WD et al (1999) Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 59:3192–3198PubMedGoogle Scholar
  9. 9.
    Sawicki LM, Buchbender C, Boos J et al (2017) Diagnostic potential of PET/CT using a 68 Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience. Eur J Nucl Med Mol Imaging 44:102–107.  https://doi.org/10.1007/s00259-016-3360-2 CrossRefPubMedGoogle Scholar
  10. 10.
    Sathekge M, Lengana T, Modiselle M et al (2017) 68 Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients. Eur J Nucl Med Mol Imaging 44:689–694.  https://doi.org/10.1007/s00259-016-3563-6 CrossRefPubMedGoogle Scholar
  11. 11.
    Kinoshita Y, Kuratsukuri K, Landas S et al (2006) Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg 30:628–636.  https://doi.org/10.1007/s00268-005-0544-5 CrossRefPubMedGoogle Scholar
  12. 12.
    Nguyen DP, Xiong PL, Liu H et al (2016) Induction of PSMA and internalization of an anti-PSMA mAb in the vascular compartment. Mol Cancer Res 14:1045–1053.  https://doi.org/10.1158/1541-7786.MCR-16-0193 CrossRefPubMedGoogle Scholar
  13. 13.
    Milowsky MI, Nanus DM, Kostakoglu L et al (2007) Vascular targeted therapy with anti–prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol 25:540–547.  https://doi.org/10.1200/JCO.2006.07.8097 CrossRefPubMedGoogle Scholar
  14. 14.
    Meller B, Bremmer F, Sahlmann CO et al (2015) Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy. EJNMMI Res 5:66.  https://doi.org/10.1186/s13550-015-0145-8 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Murga JD, Moorji SM, Han AQ et al (2015) Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer. Prostate 75:242–254.  https://doi.org/10.1002/pros.22910 CrossRefPubMedGoogle Scholar
  16. 16.
    Sathekge M, Modiselle M, Vorster M et al (2015) 68Ga-PSMA imaging of metastatic breast cancer. Eur J Nucl Med Mol Imaging 42:1482–1483.  https://doi.org/10.1007/s00259-015-3066-x CrossRefPubMedGoogle Scholar
  17. 17.
    Bühler P, Wolf P, Elsässer-Beile U (2009) Targeting the prostate-specific membrane antigen for prostate cancer therapy. Immunotherapy 1:471–481.  https://doi.org/10.2217/imt.09.17 CrossRefPubMedGoogle Scholar
  18. 18.
    Tykvart J, Navrátil V, Sedlák F et al (2014) Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA). Prostate 74:1674–1690.  https://doi.org/10.1002/pros.22887 CrossRefPubMedGoogle Scholar
  19. 19.
    Sasikumar A, Joy A, Nair BP et al (2017) False positive uptake in bilateral gynecomastia on 68 Ga-PSMA PET/CT Scan. Clin Nucl Med 42:e412–e414.  https://doi.org/10.1097/RLU.0000000000001742 CrossRefPubMedGoogle Scholar
  20. 20.
    Malik D, Basher RK, Mittal BR et al (2017) 68 Ga-PSMA expression in pseudoangiomatous stromal hyperplasia of the breast. Clin Nucl Med 42:58–60.  https://doi.org/10.1097/RLU.0000000000001445 CrossRefPubMedGoogle Scholar
  21. 21.
    Gordon IO, Tretiakova MS, Noffsinger AE et al (2008) Prostate-specific membrane antigen expression in regeneration and repair. Mod Pathol 21:1421–1427.  https://doi.org/10.1038/modpathol.2008.143 CrossRefPubMedGoogle Scholar
  22. 22.
    Ardies PJ, Gykiere P, Goethals L et al (2017) PSMA uptake in mediastinal sarcoidosis. Clin Nucl Med 42:303–305.  https://doi.org/10.1097/RLU.0000000000001543 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Yuri Tolkach
    • 1
  • Heidrun Gevensleben
    • 1
  • Ralph Bundschuh
    • 2
  • Aydan Koyun
    • 1
  • Daniela Huber
    • 3
  • Christina Kehrer
    • 3
  • Thomas Hecking
    • 3
  • Mignon-Denise Keyver-Paik
    • 3
  • Christina Kaiser
    • 3
  • Hojjat Ahmadzadehfar
    • 2
  • Markus Essler
    • 2
  • Walther Kuhn
    • 3
  • Glen Kristiansen
    • 1
    Email author
  1. 1.Institute of Pathology, Center for Integrated OncologyUniversity Hospital Bonn, University of BonnBonnGermany
  2. 2.Department of Nuclear Medicine, Center for Integrated OncologyUniversity Hospital Bonn, University of BonnBonnGermany
  3. 3.Department of Obstetrics and Gynecology, Center for Integrated OncologyUniversity Hospital Bonn, University of BonnBonnGermany

Personalised recommendations